Treatment with the PI3K/ CK1ε inhibitor umbralisib showed fewer immune-mediated adverse reactions compared to PI3K inhibitor therapy H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE TAMPA, Fla. — Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL. Early-stage CLL patients often do not require therapy,...
Tag: <span>hematologist</span>
Post
For acute myeloid leukemia, genetic testing is often worth the wait
Study suggests the benefits of a more personalized therapy typically outweigh the risks of delaying treatment to await test results AMERICAN SOCIETY OF HEMATOLOGY PRINT E-MAIL New tailored therapies offer exciting prospects for treating acute myeloid leukemia (AML), but taking advantage of them may require waiting a week or more for genetic testing before starting...
Post
The return of Vioxx: Can a drug once deemed deadly be relaunched to treat rare disease?
By DAMIAN GARDE @damiangarde OCTOBER 9, 2019 Since its recall in 2004, the pain drug Vioxx has been a symbol of pharmaceutical danger, starring in countless daytime legal advertisements explaining how you, or perhaps a loved one, might be entitled to millions in settlement dollars. But one company believes the infamous drug deserves a second...